Allogeneic anti-PSMA CAR‑NK cell therapy for metastatic castration‑resistant prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an early‑phase, interventional trial giving allogeneic anti‑PSMA CAR‑NK cells to men with PSMA‑positive metastatic castration‑resistant prostate cancer. Participants must have castrate‑level testosterone, evidence of disease progression (rising PSA or new radiographic lesions), ECOG 0–2, and expected survival of at least six months. The study will primarily monitor safety and tolerability and collect preliminary signs of anti‑tumor activity using PSA trends and radiographic assessments (RECIST and bone scans). Treatment is delivered as engineered NK cell infusions with scheduled follow‑up to watch for adverse events and response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years, male;
* Diagnosis of metastatic castration-resistant prostate cancer (mCRPC) meeting the following criteria: ① Serum testosterone at castration level: \< 50 ng/dL or \< 1.7 nmol/L; ② Meeting any one of the following conditions: a. PSA progression: Three consecutive rises in PSA measured at intervals of at least 1 week, with two increases being ≥ 50% above the PSA nadir, and a PSA value \> 2 ng/mL; b. Radiographic progression: Two or more new lesions detected on bone scan, or an increase in soft tissue lesions assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).
* Expected survival ≥ 6 months;
* ECOG performance status of 0-2;
* Positive prostate-specific membrane antigen (PSMA) expression;
* Voluntarily participate, provide written informed consent, and be able to comply with follow-up.

Exclusion Criteria:

* Prior treatment with other cell therapy products besides the investigational product, such as dendritic cells (DC), cytokine-induced killer cells (CIK), T cells, natural killer cells (NK), chimeric antigen receptor T-cell immunotherapy (CAR-T), etc.;
* History of other malignancies within 5 years prior to screening (except for completely resolved carcinoma in situ or malignancies deemed by the investigator to be slow-progressing);
* Abnormal function of major organs: a. Absolute neutrophil count (ANC) \< 1.5 × 10⁹/L; Platelet count (Plt) \< 100 × 10⁹/L; Hemoglobin (Hb) \< 9 g/dL; b. Liver function: Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≥ 2.5 × the upper limit of normal (ULN) (or ≥ 5 × ULN for subjects with liver metastases); c. Renal function: Serum creatinine (Cr) ≥ 1.5 × ULN; d. Coagulation function: Prothrombin time (PT), Activated partial thromboplastin time (APTT), International Normalized Ratio (INR) ≥ 1.5 × ULN;
* Any currently treated active (viral, bacterial, fungal) infection, or any infection within the past 6 weeks requiring intravenous antibiotics for 7 days or longer, or any active infection requiring oral antibiotics within the past week;
* Active autoimmune disease, or history of severe autoimmune disease requiring long-term immunosuppressive therapy;
* Participation in another clinical trial study within 3 months;
* Inability to employ effective contraceptive measures;
* History of hypersensitivity to biologic macromolecular drugs;
* Untreated chronic active hepatitis B, or chronic hepatitis B virus carriers with HBV DNA ≥ 1000 copies/mL, or patients with active hepatitis C;
* Subjects deemed by the investigator to be unsuitable for participation in this study for other reasons.

Where it's running

• Cancer Hospital Chinese Academy of Medical Sciences
  Beijing, 不限, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Allogeneic anti-PSMA CAR-NK cell therapy for metastatic castration-resistant prostate cancer

  This trial tests an off-the-shelf CAR-NK cell therapy that targets PSMA to see if it is safe and helps men with metastatic castration-resistant prostate cancer.

  Recruiting Early Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07156045

• MBRC-201 dose-finding and safety in advanced metastatic solid tumors

  We will test different doses of an antibody-drug conjugate called MBRC-201 in adults whose advanced metastatic cancers (including prostate, breast, colorectal, lung, and pancreatic cancer) have not responded to standard treatments.

  Recruiting at 7 sites Phase 1/2 MBrace Therapeutics · San Francisco, California and 6 other locations · NCT07145255

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer

  This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Hebei, Hebei · NCT07906587

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.